Management of Homozygous Familial Hypercholesterolemia (HoFH)

Eliot Brinton, MD, opens a discussion surrounding the treatment landscape for patients with homozygous familial hypercholesterolemia (HoFH).

Dr Brinton provides insights regarding prognosis for patients with HoFH.

Medical experts illustrate an array of characteristics presented in patients with HoFH.

Early testing for HoFH may lead to significant improvement in patient prognosis.

Seth Baum, MD, and Erin Michos, MD, MHS, discuss pediatric diagnosis of homozygous FH.

Dr Brinton provides an overview of guideline-directed therapies in HoFH.

Key opinion leaders discuss drivers in health care utilization for patients diagnosed with HoFH.

The treatment landscape of HoFH is discussed by Eliot Brinton, MD.

Drs Brinton and Michos highlight LDL-C apheresis in the treatment landscape for homozygous familial hypercholesterolemia [HoFH].

Experts discuss the effect and safety of lomitapide and evinacumab in treating patients with HoFH.

Evinacumab is highlighted as a new therapy for treating patients with homozygous FH.

Drs Baum and Michos share insights on current barriers to access of care.

Considerations for authorization documentation in HoFH treatment are discussed.

Drs Michos and Baum provide payer considerations regarding HoFH treatment pathways.

Medical experts discuss the unmet needs surrounding homozygous FH.

In their final thoughts, Drs Brinton, Baum and Michos provide insights on the trajectory of treatment in HoFH.